| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
|
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Considerations for Drug Development in Myelodysplastic Syndromes |
|
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls? |
|
Haematologica |
Aplastic Anemia |
| Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
